Adverse events during the titration phase of interferon-beta in remitting-relapsing multiple sclerosis are not predicted by body mass index nor by pharmacodynamic biomarkers

Munoz, Delicias; Escartin, Antonio; Dapena, Dolores; Coret, Francisco; Fernandez-Uria, Dionisio; Perez, Domingo; Casanova, Bonaventura; Guijarro-Castro, Cristina; Munteis, Elvira; del-Campo Amigo, Mara; Pego, Robustiano; Calles, Carmen; Garcia-Rey, Cesar; Monsalve, Nuria; Sanchez-Matienzo, David

doi:10.1186/1471-2377-13-82

Identifier to cite or link to this item: http://hdl.handle.net/20.500.13003/12821

View

000321782000001.pdf (204.3Kb)

Identifiers

URI: http://hdl.handle.net/20.500.13003/12821

DOI: 10.1186/1471-2377-13-82

ISSN: 1471-2377

WOS ID: 000321782000001

Scopus EID: 2-s2.0-84880023437

PMID: 23845043

Embase PUI: L52683151

Metrics

Export

External links

Publication date

2013-07-11

Document type

research article

Citation

Muñoz D, Escartin A, Dapena D, Coret F, Fernandez-Uria D, Perez D, et al. Adverse events during the titration phase of interferon-beta in remitting-relapsing multiple sclerosis are not predicted by body mass index nor by pharmacodynamic biomarkers. BMC Neurol. 2013 Jul 11;13:82.

Abstract

Background: This study aimed to correlate body mass index or biomarkers with the frequency of common adverse events (AEs) with subcutaneous IFN beta-1a during treatment titration in patients with relapsing-remitting multiple sclerosis previously naive to IFN beta. Methods: Eighty-four patients (66.3% females) were followed up during 8 weeks, 25.3% were overweight and 14.5% were obese. Results: Biomarkers steadily increased during all study period by 45.3% for beta 2-microglobulin, 262.8% for olygoadenylate synthetase-1, and 92.8% for neopterin. Overall AE reporting did not vary with the dose or treatment duration. Conclusions: BMI was not predictive of increased risk for AEs. Biomarkers did not discriminate on the frequency of any AE either.